Get the Stockscreener App
4.90
1.01%
-0.05
After Hours:
4.95
0.05
+1.02%
Champions Oncology Inc stock is traded at $4.90, with a volume of 8,796.
It is down -1.01% in the last 24 hours and down -1.61% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$4.95
Open:
$4.81
24h Volume:
8,796
Relative Volume:
0.83
Market Cap:
$68.20M
Revenue:
$57.94M
Net Income/Loss:
$-2.34M
P/E Ratio:
-29.41
EPS:
-0.1666
Net Cash Flow:
$3.82M
1W Performance:
-7.55%
1M Performance:
-1.61%
6M Performance:
-15.52%
1Y Performance:
-23.32%
1-Day Range:
$4.8001
$4.955
1-Week Range:
$4.8001
$5.31
52-Week Range:
$4.59
$8.3099
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
4.90 | 68.20M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Champions Oncology Inc (2I3.MU) cash flow - au.finance.yahoo.com
Is Champions Oncology (NASDAQ:CSBR) Stock Worth Watching Today? - Kalkine Media
Champions Oncology Q4FY26 Results: Revenue up 12% to $59.4 million - scanx.trade
Full Transcript: Champions Oncology Q4 2026 Earnings Call - Benzinga
Champions Oncology, Inc.Common Stock (Nasdaq:CSBR) Price Chart - The Chronicle-Journal
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth - Eastern Progress
Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ... - Yahoo Finance
Champions Oncology Narrows Q1 Loss to $426,000 - Minichart
CHAMPIONS ONCOLOGY, INC. 1Q 2027: Revenue $15.23M, EPS $(0.03) — 10-Q Summary - TradingView
CSBR 10-Q FilingsChampions Oncology, Inc. SEC 10-Q - stocktitan.net
Champions Oncology Q4 Results: Adjusted EPS beats estimates - scanx.trade
Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript - The Globe and Mail
Champions Oncology, Inc. Q1 2027 Earnings Call Summary - Yahoo Finance
CSBR|Champions Oncology Inc|Price:5.096|Chg%:+0.086 - TradingKey
Champions Oncology posts 8.8% revenue growth an... - Pluang
Champions Oncology Fiscal Q1 2027 Earnings: Margin Expansion Lifts Adjusted EBITDA - TradingKey
Earnings call transcript: Champions Oncology tops Q1 2027 estimates, shares slip - Investing.com Nigeria
Champions Oncology Q1 Results: Adj. EPS up 400% to $0.05 - scanx.trade
Champions Oncology (CSBR) Q1 Fiscal 2027 Earnings Call: Revenue Up 9%, Services Margin Reaches 51% - TradingKey
Champions Oncology Q1 Earnings Call Highlights - Yahoo Finance
Champions Oncology earnings beat by $0.06, revenue topped estimates - Investing.com
Champions Oncology reports Q1 revenue $15.2M, adjusted EBITDA $0.7M and oncology services margin 51% - TradingView
CSBR: Revenue up 8.8% to $15.2M, oncology margin at 51%, adjusted EBITDA $671K, net loss $426K - TradingView
Champions Oncology posts better-than-expected Q1, but shares edge lower on higher costs - Investing.com
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026 - marketscreener.com
CHAMPIONS ONCOLOGY ($CSBR) Releases Q1 2027 Earnings - Quiver Quantitative
Champions Oncology Reports Revenue of $15.2 Million - ACCESS Newswire
Oracle, Adobe, Copart and more set to report earnings Thursday By Investing.com - Investing.com Australia
Oracle, Adobe, Copart and more set to report earnings Thursday - Investing.com
CSBR Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026 - Black Hills Pioneer
Champions Oncology Inc. (CSBR) Key Financial Ratios – Valuation, Profitability & More - Value Research
CSBR - Finviz
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging - New Castle News
New imaging follows cancer treatments inside tumors—and links uptake to response - Stock Titan
Champions Oncology adds in-house SPECT/CT imaging to radiopharma platform - scanx.trade
Champions Oncology Inc. (CSBR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Champions Oncology Inc. (CSBR) Peer Comparison – Compare with Others - Value Research
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Champions Oncology Inc (NASDAQ: CSBR) Share Price, CSBR Stock News, CSBR Share Price & Updates - kalkine.ca
Champions (CSBR) Range: Finishes 4.86% Up at $5.18 in the Latest Session; Price Setup: the Near-Term Reference Band Stretches From $4.92 to $5.44 in the Available RecordHidden Order - vinanet.vn
North-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Japan Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Rest-Of-Asia-Pacific Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Latin-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Comedian Michael Kosta Headlines Karmanos Comedy Champions on New October Date, Hosted by 101 WRIF's Jade Springart - PR Newswire
Precision Trading with Champions Oncology Inc. (CSBR) Risk Zones - Stock Traders Daily
OSTX Stock Price and Chart — AMEX:OSTX - TradingView
Manulife China Bank Life Champions Early Health Action and Financial Planning at The Art of Longevity - Mindanao Times
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer - The ASCO Post
China Patient Derived Xenografts/PDX Models Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):